Latest Announcements

Alembic Pharmaceuticals Ltd announced its unaudited financial results for Q1 FY27, with revenue increasing by 26% YoY to INR 21.50 Bn, driven by 49% YoY growth in US Formulation and 33% YoY growth in API. EBITDA margin improved to ~24%, with a 7% YoY growth in EBITDA before R&D. The company reported a 33% YoY growth in PAT to INR 1.73 Bn, supported by a strong order book.

Suzlon Energy Limited has informed the Exchange about the Transcript of Q1 FY27 Earnings Conference Call, which is available on the company's website (www.suzlon.com).

Regis Industries Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, with a net profit of Rs. 197.68 lakhs and an EPS of Rs. 0.08. The company's revenue from operations was Rs. 583.23 lakhs, with a cost of materials consumed of Rs. 375.69 lakhs. The board of directors approved the financial results at their meeting held on August 4, 2026.

Emami Ltd reports 15% topline growth, with domestic business growing 20% and international business declining 12% due to West Asia disruptions. The company delivered a strong quarter despite external headwinds, with EBITDA growing 6% to ₹226 crore and Profit Before Tax growing 4% to ₹195 crore.

Alembic Pharmaceuticals Limited has informed the Exchange about Investor Presentation on Unaudited Financial Results for the quarter ended 30th June, 2026. The presentation highlights a 26% YoY growth in revenue, with key highlights including a 7% YoY growth in India Branded Business, 49% YoY growth in US Formulation, and 33% YoY growth in R&D. The company also reported a 33% YoY growth in PAT, supported by a strong order book.

Repro India Ltd reported a 20% YoY growth in consolidated Q1 FY27 revenue, reaching Rs 141 cr, the highest quarterly revenue in its history. The company's digital biz vertical grew by 11% YoY, with the platform vertical growing by 24% YoY to Rs 74 cr, reaching an annualized run-rate of Rs 300 cr. The company has reported an exceptional gain of Rs 167 cr on account of income received from Mahape land sale.

Alembic Pharmaceuticals Limited has submitted its financial results for the quarter ended June 30, 2026, with the Board of Directors approving the consolidated and standalone unaudited financial results along with the Limited Review Report issued by the Statutory Auditors.

Graphite India Ltd has announced unaudited financial results for the quarter ended 30th June, 2026. The company reported a profit of ₹157 crore, with earnings per share (EPS) at ₹8.02. Revenue from operations was ₹765 crore, and total expenses were ₹674 crore. The company's segment revenue was ₹765 crore, with Graphite and Carbon segment contributing ₹651 crore. The company's total assets were ₹7,228 crore, and total liabilities were ₹1,437 crore.

Emami Ltd reported a 15% growth in consolidated revenues to ₹1,039 crore for the quarter ended June 2026, driven by a 20% growth in domestic business. EBITDA grew 6% to ₹226 crore despite higher input costs. The company made strategic investments in Axiom Ayurveda and IncNut, and remains optimistic about its growth prospects.

Wonderla Holidays Limited has submitted its financial results for the quarter ended June 30, 2026, with a profit before tax of Rs. 9,346.54 lakhs and a total revenue of Rs. 25,210.21 lakhs. The company has also allotted 15,105 shares to employees and granted 8,980 stock options to two employees.

Repro India Limited has informed the Exchange about Investor Presentation, showcasing Q1 FY27 performance highlights, including 20% YoY revenue growth, stable gross margins, and exceptional gain from Mahape land sale.

Emami Limited reported a 15% topline growth in Q1FY27, with consolidated revenues reaching ₹1,039 crore. Domestic Business grew 20%, while International Business declined 12% due to West Asia disruptions. EBITDA grew 6% to ₹226 crore despite higher input costs.

Emami Limited has reported a 15% topline growth in Q1FY27, with domestic business growing 20% and international business declining 12% due to West Asia disruptions. The company has also made strategic investments to strengthen its future growth portfolio.

Morepen Laboratories Limited has announced its financial results for Q1 FY27, reporting its highest-ever quarterly revenue and earnings, supported by better operating leverage, improved performance on API front, strong export growth and full scale commercialization of CDMO mandate.

Morepen Laboratories Ltd reported its highest-ever quarterly revenue and earnings in Q1 FY27, with EBITDA growing by 207% and PAT by 394%. The company's CDMO mandate entered full scale commercialization phase, with Rs. 58 Cr worth of commercial CDMO dispatches already completed during the quarter.

Dr. Agarwal's Health Care Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026, with revenue from operations growing by 26.0% YoY to ₹614 Crores, and PAT growing by 44.6% YoY to ₹55 Crores.

Indian Metals & Ferro Alloys Ltd (IMFA) has reported record revenue and robust financial performance in Q1 FY27, driven by higher volumes and firm prices. The company's Greenfield Expansion Project at Kalinganagar is on track, and all four furnaces at KNR 2 are operational. IMFA has also signed a long-term offtake arrangement for additional 65 MWp hybrid renewable energy and is nearing completion of its ethanol project.

Indian Metals & Ferro Alloys Ltd (IMFA) reported record revenue and robust financial performance in Q1 FY27, driven by higher ferro chrome output and firm prices. The company's Greenfield Expansion Project at Kalinganagar is on track, with the first furnace expected to be commissioned in August 2026 and the second furnace in September 2026. IMFA has also signed a long-term offtake arrangement with Enfinity Global for an additional 65 MWp hybrid renewable energy, expected to be available by June 2027.

Dr. Agarwal's Health Care Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026, with revenue from operations growing by 26.0% YoY to ₹614 Crores, total income growing by 23.9% YoY to ₹620 Crores, IND-AS EBITDA growing by 25.2% YoY to ₹177 Crores, and PAT growing by 44.6% YoY to ₹55 Crores.

Morepen Laboratories Ltd has released its Q1 FY 27 Investor Presentation, highlighting a 34% YoY increase in revenue, 207% YoY increase in EBITDA, and 394% YoY increase in PAT. The company attributes this performance to operational execution and commercial validation of its Morepen 2.0 strategy.